{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:15:46Z","timestamp":1792678546352,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007642","name":"Direction de la Recherche Clinique et de l\u2019Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jbspin.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T12:59:11Z","timestamp":1528289951000},"page":"195-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis"],"prefix":"10.1016","volume":"86","author":[{"given":"Minh Vu Chuong","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athan","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2222-1456","authenticated-orcid":false,"given":"Xavier","family":"Romand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Trocm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Courtier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1177-9497","authenticated-orcid":false,"given":"Hubert","family":"Marotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Miossec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"T\u00e9bib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3288-2015","authenticated-orcid":false,"given":"Laurent","family":"Grange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lequerr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2018.05.006_bib0220","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/ard.62.8.764","article-title":"Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study","volume":"62","author":"Maillefert","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0225","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/BOR.0b013e32835fc62e","article-title":"Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis","volume":"25","author":"Navarro-Mill\u00e1n","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0230","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0235","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jama.2016.13512","article-title":"Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial","volume":"316","author":"Gottenberg","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0240","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0245","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3111\/13696998.2014.893241","article-title":"Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting","volume":"17","author":"Meissner","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0250","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jbspin.2010.02.026","article-title":"Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis","volume":"77","author":"Marotte","year":"2010","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0255","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1136\/ard.2008.093153","article-title":"Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis","volume":"68","author":"Trocm\u00e9","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0260","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/rheumatology\/kep452","article-title":"Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases","volume":"49","author":"Baillet","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0265","doi-asserted-by":"crossref","first-page":"e115800","DOI":"10.1371\/journal.pone.0115800","article-title":"Identification of S100A9 as biomarker of responsiveness to the methotrexate\/etanercept combination in rheumatoid arthritis using a proteomic approach","volume":"9","author":"Obry","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0270","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13075-015-0553-1","article-title":"Haptoglobin-\u03b11, -\u03b12, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis","volume":"17","author":"Blaschke","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0275","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2249.2008.03691.x","article-title":"Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis","volume":"153","author":"Fabre","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0280","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1002\/art.40127","article-title":"Brief report: genetic variation of the \u03b11-antitrypsin gene is associated with increased autoantibody production in rheumatoid arthritis","volume":"69","author":"McCarthy","year":"2017","journal-title":"Arthritis Rheumatol Hoboken"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0285","first-page":"394","article-title":"Transthyretin as a potential serological marker for the diagnosis of patients with early rheumatoid arthritis","volume":"31","author":"Ni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0290","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0295","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/ard.51.2.177","article-title":"Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis","volume":"51","author":"van der Heijde","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0300","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0305","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0310","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/0895-4356(91)90128-V","article-title":"Likelihood ratios with confidence: sample size estimation for diagnostic test studies","volume":"44","author":"Simel","year":"1991","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0315","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat Med"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0320","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/tpj.2015.29","article-title":"Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis","volume":"16","author":"Ferreiro-Iglesias","year":"2016","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0325","doi-asserted-by":"crossref","first-page":"342524","DOI":"10.1155\/2014\/342524","article-title":"Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis","volume":"2014","author":"Duroux-Richard","year":"2014","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0330","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/ard.2011.153023","article-title":"Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis","volume":"70","author":"Takeuchi","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0335","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2016","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0340","first-page":"2158","article-title":"Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response","volume":"34","author":"Pachot","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0345","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7150\/thno.12403","article-title":"Identification of 7 proteins in sera of RA patients with potential to predict ETA\/MTX treatment response","volume":"5","author":"Obry","year":"2015","journal-title":"Theranostics"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0350","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed Rep"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0355","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","article-title":"2016 update of the EULAR recommendations for the management of early arthritis","volume":"76","author":"Combe","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0360","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","author":"Smolen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0365","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","article-title":"Assessing remission in clinical practice","volume":"46","author":"Mierau","year":"2007","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0370","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1189\/jlb.0105024","article-title":"Regulated expression of platelet factor 4 in human monocytes--role of PARs as a quantitatively important monocyte activation pathway","volume":"78","author":"Schaffner","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0375","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1136\/annrheumdis-2014-206921","article-title":"Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis","volume":"75","author":"Yeo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0380","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejcb.2010.12.002","article-title":"Molecular pathways of platelet factor 4\/CXCL4 signaling","volume":"90","author":"Kasper","year":"2011","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0385","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF00270285","article-title":"Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis","volume":"9","author":"Endresen","year":"1989","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0390","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s100670200123","article-title":"Elevated plasma levels of beta-thromboglobulin and platelet factor 4 in patients with rheumatic disorders and cutaneous vasculitis","volume":"21","author":"Yamamoto","year":"2002","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0395","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/156652413804486214","article-title":"Functions of S100 proteins","volume":"13","author":"Donato","year":"2013","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0400","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaci.2006.08.021","article-title":"S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity","volume":"119","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0405","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1189\/jlb.69.6.986","article-title":"Proinflammatory properties of the human S100 protein S100A12","volume":"69","author":"Yang","year":"2001","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0410","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.amjcard.2004.05.076","article-title":"Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease","volume":"94","author":"Ye","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0415","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/1471-2474-15-335","article-title":"The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab","volume":"15","author":"Nordal","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0420","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/03009742.2015.1107128","article-title":"Calprotectin (S100A8\/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab","volume":"45","author":"Nordal","year":"2016","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0425","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1152\/physiolgenomics.00127.2010","article-title":"Gene expression profiling in peripheral blood cells of patients with rheumatoid arthritis in response to anti-TNF-alpha treatments","volume":"43","author":"Meugnier","year":"2011","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.jbspin.2018.05.006_bib0430","doi-asserted-by":"crossref","first-page":"e93905","DOI":"10.1371\/journal.pone.0093905","article-title":"Identification of autoantibodies against transthyretin for the screening and diagnosis of rheumatoid arthritis","volume":"9","author":"Sharma","year":"2014","journal-title":"PloS One"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18301064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X18301064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:24:30Z","timestamp":1761150270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X18301064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1297319X18301064"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.05.006","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prealbumin, platelet factor 4 and S100A12 combination at baseline predicts good response to TNF alpha inhibitors in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}